Rigel Pharmaceuticals, Inc. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +16.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.91 | $0.88 | -3.3% | Miss | Q2 FY26 call |
| Q1 FY26 | $0.74 | $0.44 | -40.5% | Miss | |
| Q4 FY25 | $1.33 | $1.14 | -14.3% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.93 | $1.46 | +57.0% | Beat | |
| Q2 FY25 | $1.97 | $3.28 | +66.5% | Beat | |
| Q1 FY25 | not reported | $0.63 | not reported | not reported | |
| Q4 FY24 | $0.55 | $0.80 | +45.5% | Beat | |
| Q3 FY24 | not reported | $0.70 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY24 | $-0.03 | $-0.05 | -66.7% | Miss | |
| Q4 FY23 | $-0.03 | $0.00 | +100.0% | Beat | |
| Q3 FY23 | $-0.07 | $-0.03 | +57.1% | Beat |
Back to RIGL overview · RIGL holders · RIGL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.